The COVID-19 pandemic exposed the risks and fragility inherent in global pharmaceutical and biotechnology supply chains. This isn’t really news though. For some time, these supply chains have lagged other industries in speed, flexibility, agility, redundancy, and diversification. With risk considerations at the forefront resulting from shortages during the pandemic, the US government is [...]
Converge develops commercial supply chain business processes, commercial systems architecture & last mile strategies. Our client was an emerging pharmaceutical company focused on rare diseases, in clinical trials with an ultra-orphan drug. There were two competitive therapies also in development, so they began preparations for commercial launch on a compressed timeline to [...]
On February 24, 2021, President Biden signed an Executive Order on America’s Supply Chains (EO) as a step toward building more secure, robust and resilient supply chains. The EO initiated a 100-Day Supply Chain Review, which detailed an assessment of the strengths and weaknesses of the domestic supply chains for four key product areas, one of which included a review of pharmaceuticals and [...]
Jeremy Friedler, senior consultant, and Rashi Gupta, consultant, focus on biotechnology and pharmaceutical operations at Converge Consulting. The COVID-19 pandemic and resulting economic crisis exposed the vulnerabilities of both domestic and global supply chains across multiple industries. Given the complexity and far-reaching global nature of their supply chains, pharmaceutical and biotechnology companies were [...]
Life Sciences Supply Chain Working Group Webinar on June 29 @ 11a-12p Request the Presentation Request the Recording The Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, signed in March 2020, provides emergency assistance and health care response for individuals, families, and businesses affected by the [...]
The current pandemic is severely impacting life science supply chains. There are supply delays, constrained transportation and cold storage, and reduced demand. As the pandemic begins to ease in some parts of the world, Supply Chain leaders are preparing for the post-pandemic global logistics and trade environment. Our Life Sciences Supply Chain Working Group (SCWG) [...]
As life science companies advance beyond the first launch of commercial products, strategic focus shifts. Attention moves to expanding the business, regulatory and geographic reach of their treatments. Market expansion, label expansion, and further pipeline development create more opportunities. Companies pursue these efforts in parallel as quickly as possible. The initial supply and [...]
Preparing for commercial launch is a complex process for most any life science company. Adding to the challenge, many emerging life sciences companies operate as very lean organizations with limited resources. Specialty products in particular can be one-of-a-kind and require unique launch processes and procedures. In some cases, team members are also doing it [...]
PDF Available > Cellular and regenerative medicine introduces a shift in healthcare - the promise of using the body’s own abilities to heal. Innovation in this area is driving dramatic change in the prevention, treatment and cure of diseases and disorders. The nature of cell and gene therapies (CGT) requires rethinking traditional business models [...]
Life Sciences Supply Chain Working Group Webinar on 3/25/21 @ 12-1p Request the Presentation Request the Recording We are seeing new global logistics and trade challenges emerging in our "new normal" business environment, which includes fast-changing trade wars, restrictions on cross-border transport, and huge demands for [...]